




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12Q 1/68 // C07H 21/04	A1	(11) International Publication Number: WO 92/01812 (43) International Publication Date: 6 February 1992 (06.02.92)
(21) International Application Number: PCT/EP91/01398 (22) International Filing Date: 23 July 1991 (23.07.91) (30) Priority data: 9016163.9 24 July 1990 (24.07.90) GB (71) Applicant (for all designated States except US): CEMU BIO-TEKNIK AB [SE/SE]; Banergatan 21, S-752 37 Uppsala (SE). (72) Inventor; and (75) Inventor/Applicant (for US only) : UHLEN, Mathias [SE/SE]; Kvarnbogatan 30, S-752 39 Uppsala (SE). (74) Agent: HOLMES, Michael, John; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i>

(54) Title: COMPETITIVE PCR FOR QUANTITATION OF DNA**(57) Abstract**

The invention provides a method of determining the amount of target DNA in a sample which comprises the steps of (a) dividing the sample into a plurality of aliquots; (b) adding to each aliquot a known amount of competitor DNA which is the same as the target DNA except that it comprises a recognition site capable of being detected directly or indirectly by a labelled species whereby the ratio of target DNA to competitor DNA is different in the aliquots; (c) co-amplifying the target DNA and competitor DNA in each aliquot by the polymerase chain reaction (PCR) using at least one primer which permits immobilisation of the co-amplified DNA, the annealing sites of any PCR primers used being outward of the recognition site; (d) labelling the amplified competitor DNA; (e) before or after step (d), immobilising the co-amplified DNA where not already immobilised, via at least one PCR primer; (f) assessing the amount of label on the immobilised amplified competitor DNA in each aliquot to provide an indication of the amount of target DNA in the sample.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

COMPETITIVE PCR FOR QUANTITATION OF DNA

5 This invention relates to a method of quantifying DNA in particular a method of solid phase diagnosis of medical conditions by the identification of specific DNA.

10 Target DNA molecules are often present in cell lysates or other source materials in extremely small quantities and in order to amplify such DNA selectively, the polymerase chain reaction (PCR) method has been developed. In this technique a pair of polymerisation primers specific to known sequences of the target DNA
15 are selected, one hybridising at or near the 5' end of the coding strand and the other at or near the 5' end of the non-coding strand such that in the presence of a polymerase, each primer produces a DNA sequence extending the full length of the target DNA template.
20 If the DNA so produced is then subjected to strand separation, typically by melting at a temperature of about 90°C, the newly formed single stranded DNA sequences will hybridise to excess primer present in the mixture, usually after reducing the temperature to the
25 range suitable for annealing, whereupon in the presence of the polymerase, further DNA strands are synthesised, this time extending only between the termini of the two primers. The polymerase is preferably capable of surviving the high temperature used in the strand
30 separation step, a suitable thermophilic polymerase, namely Taq, having recently become available. If an excess of the two primers and of nucleotides needed for DNA synthesis is maintained in the medium, it is possible to operate a repeated cyclic process in which
35 the separate strands are synthesised, separated, annealed to primer and new strands synthesised, merely by raising and lowering the temperature between the optimal temperatures for each of the above stages. In

- 2 -

this way, it is found that amplification of the original target DNA can be exponential and million-fold increases of concentration can be effected in a relatively short time.

5 However, this procedure is not always sufficiently selective due to a percentage of non-specific binding of the primers to other DNA sequences, thereby amplifying the latter in addition to the target DNA. Moreover, there is a need to establish how much target DNA was
10 present in a sample before PCR amplification.

 In the detection of bacteria, virus and parasites for example PCR has several advantages compared to conventional diagnostic methods, i.e. the generality and speed of the assay. However, the fact that conventional
15 PCR assays are only qualitative limits their use to diagnostic applications where only the presence or absence of the pathogen is to be determined. For many diseases, a quantitative measurement is need to make a proper diagnosis and advantageously it would be useful
20 to be able to measure the amount of pathogen during treatment to make a relevant prognosis. As mentioned above, there is major concern regarding the usefulness of PCR assay because their extreme sensitivity makes it possible to obtain false positives as a result of single
25 molecules contaminating the sample. There is a need for a quantitative assay, e.g. one suitable for clinical assays, which overcomes the drawbacks associated with conventional PCR assays.

 Recently, several systems to quantify the initial
30 template DNA/RNA have been described (A. C. Syvänen, M. Bengtström, J. Tenhunen and H. Söderlund Nucl. Acids Res., 16, 11327 (1988); G. Gilliland, S. Perrin and H. F. Bunn PCR protocols, pp. 60-69, Academic Press, San Diego (1990); and M. Becker-André and K. Hahlbrock,
35 Nucl. Acids Res. 17,9437 (1990)). Affinity-based hybrid collection of isotope-labelled products has been used to determine the amount of DNA synthesized after various PCR cycles (A. C. Syvänen et al. supra). This method

- 3 -

allows for indirect determination of the initial number of target templates in the sample. However, since the efficiency of PCR varies with changes in inter alia template and nucleoside concentration, quality of polymerase etc it is difficult to establish standard conditions which would lend themselves to use in automatic or semi-automatic equipment.

Co-amplification of cDNA and chromosomal DNA has also been performed, where the genomic DNA includes a small intron sequence (G. Gilliland et al. supra). Thus, a size difference is obtained, which can be used for electrophoretic separation to determine the ratio of genomic DNA versus cDNA. Whilst the technique overcomes some of the problems associated with Syvänen et al., the method can only be used for special applications and quantification of different sized fragments is needed.

Another quantitative method is PCR aided transcript titration assay (PATTY) in which the amount of RNA is measured by adding mutated RNA to the sample, which contains or lacks a restriction site in the amplified region as compared to the target RNA (M. Becker-André supra). After cDNA synthesis, by reverse transcriptase followed by PCR the co-amplified product is thereafter restricted and analyzed by electrophoresis. The relative amount of cleaved material gives the ratio of target RNA to internal standard RNA. This method has the disadvantages that electrophoresis or restriction analysis are needed.

Earlier we described a solid phase approach for detection of immobilized amplified nucleic acids, designated DIANA (PCT/EP90/00454), which has been used for example in its preferred embodiment in the colorimetric detection of in vitro amplified DNA. The assay is based on the use of a biotinylated or otherwise functionalised PCR primer, which is used to capture in vitro amplified material on, for example, streptavidin-coated magnetic beads. The other PCR primer contains a "handle", such as a lac operator sequence, allowing

- 4 -

colorimetric detection of the captured DNA using a LacI repressor- β -galactosidase fusion protein. J. Lundeberg, J Wahlberg, M Holmberg, U Pettersson and M. Uhlen. DNA Cell Biol. 9 (4) 289 (1990)). W. Zolg, E. Scott and M. Wendlinger Am. J. Trop. Med. Hyg. 39(1), 33 (1988). The preferred form of the qualitative DIANA assay combines the advantages of the PCR method with the high specificity and stability of the biotin-streptavidin system and the simplicity of a colorimetric detection based on β -galactosidase. The strong interaction between biotin and streptavidin ($K_d=10^{-15}$ M⁻¹) accentuates the efficiency of the system. The magnetic beads as solid support ensure that no centrifugations, filtrations or precipitations are needed. (T. Hultman, S. Ståhl, E. Hornes and M. Uhlén Nucl. Acids Res. 17, 4937 (1989).

We have now discovered a method for quantifying DNA, particularly a method for determining the amount of target DNA which was present in a sample before PCR. Our method is based on competitive titration wherein amounts of target DNA are co-amplified with known amounts of competitor DNA to produce different ratios of target: competitor DNA, the competitor DNA being substantially the same as the target DNA except that it comprises a recognition site which may be detected directly or indirectly by a labelled species. Unlike the method of Becker-Andre we do not involve restriction cleavage and electrophoretic analysis.

According to the present invention there is provided a method of determining the amount of target DNA in a sample which comprises the steps of

- (a) dividing the sample into a plurality of aliquots;
- (b) adding to each aliquot a known amount of competitor DNA which is the same as the target DNA except that it comprises a recognition site capable of being detected directly or indirectly by a labelled species whereby the ratio of target DNA to competitor DNA is different in the aliquots;

- 5 -

- (c) co-amplifying the target DNA and competitor DNA in each aliquot by the polymerase chain reaction (PCR) using at least one primer which permits immobilisation of the co-amplified DNA, the annealing sites of any PCR primers used being outward of the recognition site,
- 5 (d) labelling the amplified competitor DNA;
- (e) before or after step (d), immobilising the co-amplified DNA where not already immobilised, via at least one PCR primer;
- 10 (f) assessing the amount of label on the immobilised amplified competitor DNA in each aliquot to provide an indication of the amount of target DNA in the sample.

References herein to "target DNA" are intended to encompass inter alia cDNA e.g. from retroviral RNA,

15 genomic DNA, mitochondrial DNA etc.

Performance of the method according to the invention produces a set of label values which, when plotted against the known amounts of added competitor DNA give a characteristic sigmoid curve (as will be more

20 fully appreciated from the examples which follow); the point of inflection on the curve is defined by the sharp change in the amount of labelled DNA between those aliquots in which added competitor DNA predominated and those in which target DNA predominated and is

25 approximately proportional to the amount of target DNA in the initial sample.

In general it is preferable to add different known amounts of the competitor DNA to identical aliquots of the sample, so that any possible effect of inhibitors is

30 unchanged. The competitor DNA is most conveniently added to the aliquots as a series of equally stepped dilutions, eg 1:3 or, for a more accurate result, 1:1.5. However, much higher dilutions may be useful, for example, as high as 1:100, for some purposes. About 6-

35 10 such dilutions normally give an adequate range and 8x12 microlitre wells may be used for this purpose. It is usually sufficient for diagnostic purposes to conclude that the amount of target DNA lies between the

- 6 -

amounts of competitor DNA in two or possibly three adjacent dilutions. The method of the invention thus avoids the need for determination of the actual amount of amplified target DNA although this may in some cases
5 be useful information.

Two-stage PCR (using nested primers), as described in our co-pending application PCT/EP90/00454, may be used to enhance the signal to noise ratio and thereby increase the sensitivity of the method according to the
10 invention.

Regardless of whether one-stage or two stage PCR is performed, the efficiency of the PCR is not critical since the invention relies on the sharp change in the amount of labelled DNA between different aliquots.
15 However, it is preferred to run a qualitative DIANA as a check for the presence or absence of target DNA and if run under identical conditions enables the total quantity of amplified DNA to be determined and related to the quantitative DIANA assay.

Under certain circumstances, it may be sufficient from a diagnostic point of view, to determine merely whether the amount of target DNA is above or below on critical level, for example that derived from 1000 target pathogens. In this case, PCR may be effected on
25 a single sample to which a known amount of the competitor DNA is added at the known critical level. Where the amount of target DNA is significantly greater than the amount of competitor DNA, the signal from the amplified and labelled competitor DNA will be
30 characteristically low.

Immobilisation of the co-amplified DNA may either take place as part of the PCR amplification itself, as where one or more primers are attached to a support, or alternatively one or more of the primers may carry a
35 functional group permitting subsequent immobilisation, eg. a biotin or thiol group. Where a subsequent immobilisation step is used, this may be effected before labelling, thus permitting washing of the immobilised

- 7 -

amplified DNA prior to labelling, or after the labelling step. In either case, unattached label will be removed from the immobilisation labelled DNA prior to assessment.

5 The solid support may conveniently take the form of microtitre wells, which are advantageously in the conventional 8 x 12 format, or dipsticks which may be made of polystyrene activated to bind the primer DNA (K Almar, Doctoral Theses, Royal Institute of Technology,
10 Stockholm, Sweden, 1988). The support may also comprise particles, fibres or capillaries made, for example, of agarose, cellulose, alginate, Teflon or polystyrene. The support may also comprise magnetic particles eg the superparamagnetic beads produced by Dynal AS (Oslo,
15 Norway).

Preferably sufficient cycles of PCR are performed so that a saturation level is achieved; in that way the amplified DNA contains substantially the same ratio of target DNA to competitor DNA as that present before PCR.

20 It is advantageous to provide conditions such that the competitor and target DNA are amplified equally efficiently by PCR and it is therefore important that the size and GC-content of each fragment is kept substantially the same and that the sequences where the
25 primers anneal are identical. In some instances it will also be necessary to take into account the efficiency of the cell lysis of the sample which can make some of the genomic DNA less available for the PCR. In addition, the target DNA may be part of chromosomal DNA in the
30 initial cycles, while the competitor DNA may be, for example, in the form of a small plasmid. Thus it might be necessary to adjust for the relative amplification efficiencies of these early PCR cycles.

The quantitative method according to the invention
35 may be used for general quantification of RNA and DNA both for research and clinical applications, including diagnosis of viral, bacterial and protozoan pathogens. It may also find applications in forensic medicine. The

- 8 -

assay technique is very simple and rapid, thus making it easy to automate by using a robot apparatus where a large number of samples may be rapidly analysed. Since the preferred detection and quantification is based on a colorimetric reaction a visual analysis is often
5 sufficient for evaluation.

Any suitable polymerase may be used, although it is preferred to use a thermophilic enzyme such as Taq polymerase to permit the repeated temperature cycling
10 without having to add further polymerase, e.g. Klenow fragment, in each cycle.

As mentioned above, the target DNA may be cDNA synthesised from mRNA in the sample and the method of the invention is thus applicable to diagnosis on the
15 basis of characteristic mRNA. Such preliminary synthesis can be carried out by a preliminary treatment with a reverse transcriptase, conveniently in the same system of buffers and bases to be used in the subsequent PCR steps. Since the PCR procedure requires heating to
20 effect strand separation, the reverse transcriptase will be inactivated in the first PCR cycle. When mRNA is the target nucleic acid, it may be advantageous to submit the initial sample, e.g. a serum sample, to treatment with an immobilised polydT oligonucleotide in order to
25 retrieve all mRNA via the terminal polyA sequences thereof. Alternatively, a specific oligonucleotide sequence may be used to retrieve the RNA via a specific RNA sequence. The oligonucleotide can then serve as a primer for cDNA synthesis, as described in International
30 Patent Application PCT/89EP/00304.

The recognition site may be introduced into the competitor DNA by in vitro mutagenesis of a sample of the target DNA, e.g. by the method described in International Application PCT/EP89/01417.

35 The recognition site on the competitor DNA is preferably small and exhibits a high binding specificity with the detector molecule which directly or indirectly attaches the label. For example, the recognition site

- 9 -

could be a unique sequence recognised by a DNA probe. Such a probe could be radio-labelled, for example, or be 5' end labelled using fluorescence. It is preferred however, to insert a site into the competitor DNA which
5 is recognised by a protein.

A number of proteins are known which bind to specific DNA sequences and are often involved in genetic processes such as switching operons on and off. One such protein is the lac repressor LacI which reacts with
10 the lac operon (lacOP) to inhibit transcription. Thus, if the recognition site is the DNA sequence lacOP, the label can be attached via the protein LacI. It is particularly convenient to devise a fusion protein of a DNA binding protein such as LacI with a further protein
15 which can be subsequently used for detection for example using methods based on colour fluorescence or chemiluminescence. Examples of such proteins are β -galactosidase, alkaline phosphatase and peroxidase.

It is preferred to use as a label a LacI repressor-
20 β -galactosidase fusion protein which recognises a 21 base pair lac operator sequence introduced into the competitor DNA, e.g. near the middle. The fusion protein will bind to the competitive DNA and the addition of ONPG will lead to a colour formation which
25 can be assessed spectrophotometrically. Use of this fusion protein and IPTG allows for a fast simple colorimetric assay which does not have the safety problems associated with using radio-labels.

The specificity of the process for the target DNA
30 is greatly increased by including a first-stage PCR amplification step. By such preliminary amplification, the concentration of target DNA is greatly increased with respect to other DNA which may be present in the sample and a second-stage amplification with at least
35 one primer specific to a different sequence of the target DNA, as described in PCT/EP 90/00454, significantly enhances the signal due to the target DNA relative to the 'background noise'.

- 10 -

The method of the present invention is particularly advantageous in diagnosis of pathological conditions characterised by the presence of specific DNA, particularly latent infectious diseases such as viral infection by herpes, hepatitis or HIV. Also, the method can be used with advantage to characterise or serotype and quantify bacterial, protozoal and fungal infections where samples of the infecting organism maybe difficult to obtain or where an isolated organism is difficult to grow in vitro for subsequent characterisation as in the case of *P. falciparum* or chlamydia species. Due to the method's simplicity and speed it may also be used to detect other pathological agents which cause diseases such as gonorrhoea and syphilis. Even in cases where samples of the infecting organism may be easily obtained, the speed of the PCR technique compared with overnight incubation of a culture may make the method according to the invention preferable over conventional microbiological techniques.

The solid support may carry functional groups such as hydroxyl, carboxyl, aldehyde or amino groups, or other moieties such as avidin or streptavidin, for the attachment of primers. These may in general be provided by treating the support to provide a surface coating of a polymer carrying one of such functional groups, e.g. polyurethane together with a polyglycol to provide hydroxyl groups, or a cellulose derivative to provide hydroxyl groups, a polymer or copolymer of acrylic acid or methacrylic acid to provide carboxyl groups or an aminoalkylated polymer to provide amino groups. US Patent No. 4654267 describes the introduction of many such surface coatings.

The invention also comprises kits for determining the amount of target DNA in a sample. These will normally include at least the following components:

- (a) competitor DNA comprising a recognition site which is capable of being detected directly or indirectly by a labelled species;

- 11 -

- (b) a label carrying means for attachment to amplified competitor DNA;
- (c) a pair of primers for PCR at least one primer
5 having means permitting immobilisation of said primer;
- (d) a polymerase which is preferably heat stable, for example Taq1 polymerase;
- 10 (e) buffers for the PCR reaction; and
- (f) optionally a solid support.

15 Where an enzyme label is used, the kit will advantageously contain a substrate for the enzyme and other components of a detection system.

The invention will now be described by way of non-limiting examples with reference to the drawings in
20 which:-

Figure 1 shows schematically a difference between a preferred method of qualitative DIANA and a preferred method of quantitative DIANA according to the invention;

Figure 2 is a diagram showing various primer
25 sequences, their designations and their relationship to a target sequence; and

Figure 3 shows graphically the results of experiments described below.

Figure 1 schematically shows a preferred embodiment
30 of the principle of the quantitative DIANA according to the invention, in which a solid support is used to immobilise biotinylated DNA fragment obtained after PCR and a LacI repressor- β -galactosidase fusion protein is used for the subsequent colorimetric detection. In the
35 qualitative DIANA assay a lac operator sequence is incorporated into the in vitro amplified material using a "handle" sequence in one of the PCR primers. In the quantitative DIANA assay, a lac operator sequence is

- 12 -

instead introduced into a cloned version of the target sequence that is competitive DNA and a known amount of this cloned DNA is co-amplified with the target DNA. In both cases, the detection is based on the specific interaction of the LacI- β -galactosidase fusion protein (J. Wahlberg *et al. supra*), with the lac operator sequence and the subsequent hydrolysis of the substrate orthonitrophenyl- β -D-galactoside (ONPG), to give the colorimetric response.

10

Example I

Determination of the absolute amounts of the parasite Plasmodium falciparum in clinical human blood samples.

15 The Pf155 gene was chosen as target DNA since amplification of this gene had been shown to accurately detect the presence of parasite in clinical material (J. Lundeberg, J. Wahlberg, M. Holmberg, U. Pettersson and M. Uhlén DNA Cell Biol. 9(4), 289 (1990)). The primers used to clone and assay the Pf155 gene are shown in figure 2. Primers RIT52, 53, 54 and RIT55 were used to clone the whole fragment by PCR. Template for the cloning competitive DNA was a clinical sample from The Gambia (M. Holmberg *et al.* Trans. R. Soc. Trop. Med. Hyg. 84, 202 (1990) and a 21 base pair lac operator sequence was simultaneously introduced into the cloned fragment, replacing 21 nucleotides from 1519 to 1539 of the gene.

30 Figure 2 shows the structure of the Pf155/RESA target gene of P. falciparum and the primers used for the detection, quantification and cloning. The numbers refer to the published sequence by J.M. Favaloro *et al.*, Nucl. Acids Res 14, 8265 (1986). The primers were synthesized by phosphoramidite chemistry on an automated DNA synthesis machine (Gene Assembler Plus, Pharmacia, Sweden). The PCR cloning and in vitro mutagenesis was performed by subcloning the upstream fragment of Pf155/RESA gene generated by PCR with primers RIT52 and

- 13 -

RIT54 and cleaved with BamHI and EcoRI and ligated into pUC8 digested with the same enzymes. The resulting construction was digested with BamHI and HindII to enable ligation with the downstream fragment generated by PCR and RIT53 and RIT55, digested with BamHI and HindIII. The mutant clone was verified by DNA sequencing as described by T Hultman *et al.*, Nuc Acids Res 17, 4937 1989. For the qualitative assay, RIT48 and RIT36 were used, while primers RIT48 and RIT61 were used for the quantitative DIANA. The nucleotides shown in italics correspond to sequences introduced by *in vitro* mutagenesis.

For the quantitative DIANA, a two step nested primer PCR was performed using the outer primers RIT25 and RIT53 for an initial 35 cycles and then, after dilution of the amplified material, an additional 25 cycles with the inner primers RIT48 and RIT61. The cloned competitor DNA was added in serial dilutions before the first PCR cycle to tubes containing same amount of the initial target DNA. A standard qualitative DIANA was run in parallel without the addition of competitor DNA. In this case, the downstream primer RIT61 was replaced with primer RIT36 (figure 2) containing a *lac* operator "handle" sequence. Thus, a qualitative assay to detect the presence or absence of the Pf155 gene is performed in parallel with the quantitative assay.

A lysis mixture W. Zolig, E. Scott and M. Wendlinger Am. J. Trop. Med. Hyg 39 (1) 33 (1988) corresponding to 0.2 μ l whole blood of patients from The Gambia were used and the amount of parasites were independently determined by microscopical determination.

The *in vitro* amplification was performed using a Techne Programmable Dri-Block PHC-2 (Techne, U.K.). The amplification was run in two consecutive steps; first 35 cycles with RIT52 and RIT53, followed by a 1/100 dilution and a second amplification for 25 cycles with RIT48 and RIT61 for the quantitative DIANA assay and

- 14 -

RIT48 and RIT36 for the qualitative DIANA assay. The PCR buffer used contained 20 mM TAPS (3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid) (pH 9.3), 8 mM MgCl₂, 50 mM KCl and 0.1% Tween 20.

5 The sample and a decreasing amount of competitor DNA, 1 µl each, were put into PCR tubes with 10 µl PCR buffer. The tubes were subsequently heated to 99°C for 5 minutes to lyse the cells and then rapidly cooled to 0°C. To the lysed mixture, 40 µl of a PCR buffer with

10 0.2 mM dNTP, 0.2 µM of each primer and 1.0 unit of AmpliTaq polymerase (Perkin Elmer, Sweden) was added. The reaction mixture was covered with a layer of light mineral oil (Sigma, USA). One temperature cycle on the PCR was: denaturation of template 96°C, 0.5 minute;

15 annealing of primers 59°C, 1 minute; extension of primers 72°C, 1 minute. The PCR mixture was immobilized to 300 µg of magnetic beads with covalently coupled streptavidin, Dynabeads M280-Streptavidin (Dynal AS, Norway) and incubated for 20 minutes at room

20 temperature. The beads, with the immobilized DNA, were mixed with 200 µl of fusion protein (Lac I-β-galactosidase, 0.2 mg/ml and 200 µg of sonicated herring sperm DNA in a Eppendorf tube for 20 minutes. The beads were washed four times with 250 µl TST buffer (0.1 M

25 Tris-HCl, pH 7.5, 0.15 M NaCl, 0.1% Tween 20) containing 10 mM β-mercaptoethanol. The substrate, ortho-nitrophenyl-β-D-galactoside (ONPG), was added (200 µl) and the change of absorbance at room temperature was measured. The reaction was stopped by taking half of

30 the reaction mixture to a microtitre plate with stop solution. The result is presented as the change of absorbance per minute at 405 nm.

In Figure 3, A is a titration curve with 1:1.5 serial dilution of competitor DNA using a sample

35 containing 500 parasites and B,C,D,E each show quantitative DIANA of samples using a 1:3 serial dilution of the competitor DNA with the amount of parasites per sample determined by the microscopical

- 15 -

method indicated. Lane "+/-" represents the qualitative DIANA detection of the respective sample.

Initially a sample containing approximately 500 parasites were used as template in the quantitative
5 DIANA and 1:1.5 serial dilutions of the competitor DNA containing lac operator sequence were performed, starting with approximately 16000 competitor plasmid molecules in the first step (dilution 1). Note that since the parasite is haploid in its asexual stage,
10 there is only 1 target chromosomal region per parasite. After a two step PCR procedure, biotin-containing material was immobilised by the magnetic beads. The beads were washed and fusion protein and chromogenic substrate was added. The results, presented in figure
15 3A, shows that dilutions 1 to 6 gives a high colorimetric response showing that most DNA fragments originate from the lac operator-containing competitor. In contrast, a low activity is observed for dilutions 9 to 10 showing that the target DNA, lacking the lac
20 operator, is in majority. A intermediate response is obtained for dilution 7 and 8 containing approximately 1400 and 950 competitor molecules, respectively. This shows that the quantitative DIANA assay gives a titration curve with the expected sigmoid shape,
25 although the plasmid target DNA is amplified with an approximately two-fold lower efficiency as compared to the genomic target DNA.

To allow quantification over a relatively broad range (20 to 150000 parasites/sample) without more than
30 nine serial dilutions, the assay was modified by performing 1-to-3 dilutions. Due to the two-fold lower efficiency for plasmid target DNA as compared to genomic DNA (figure 3A), 300000 plasmid molecules were added to the sample (dilution 0). Several clinical human blood
35 samples from The Gambia (Holmberg supra) were assayed in this manner and independently determined by a microscopical method (Holmberg supra). The results for four independent and representative samples are shown in

- 16 -

figure 3B,C,D and E. The qualitative DIANA show that samples B,C and D contain parasites, while sample E is negative. The quantitative DIANA for sample B shows a cut-off point between dilutions 3 and 4, which
5 represents 5550 and 1850 parasites, respectively. This result is in good agreement with the microscopical method which suggested that the sample contained approximately 2600 malaria parasites. Sample C has a cut-off point between dilutions 4 and 5 representing
10 1850 and 620 molecules, respectively, which is in good agreement with the 900 parasites detected with the microscopic method. Sample D, which contain 40 parasites, has a cut-off point at dilution 7 and 8 containing competitor molecules corresponding to 70 and
15 20 parasites, respectively. This shows that as few as 40 parasites can be detected with the assay. In contrast, all dilutions for sample E show a high colorimetric response, which is expected since this sample did not contain any parasite. It is noted that
20 the absolute values for the individual positive signals vary considerably and this is probably due to variations in efficiencies during the latter part of the PCR procedure. However, this variation does not limit the assay since only the inflexion point must be determined
25 for each sample and thus a high signal to noise ratio is sufficient. In figure 3B,C and 3D, the signal in each positive point is indeed high while the background noise is very low. The absolute values between qualitative and quantitative points also differ, probably due to
30 variations of the PCR efficiency with the two different primers (RIT61 and RIT36).

For routine analysis a positive control, e.g. β -globin gene, should be run in parallel to demonstrate that the amplification efficiencies have not been
35 reduced due to presence of inhibitors in the sample.

- 17 -

CLAIMS:

1. A method of determining the amount of target DNA in a sample which comprises the steps of
 - 5 (a) dividing the sample into a plurality of aliquots;
 - (b) adding to each aliquot a known amount of competitor DNA which is the same as the target DNA except that it comprises a recognition site capable of being detected directly or indirectly by a labelled species whereby the
 - 10 ratio of target DNA to competitor DNA is different in the aliquots;
 - (c) co-amplifying the target DNA and competitor DNA in each aliquot by the polymerase chain reaction (PCR) using at least one primer which permits immobilisation
 - 15 of the co-amplified DNA, the annealing sites of any PCR primers used being outward of the recognition site,
 - (d) labelling the amplified competitor DNA;
 - (e) before or after step (d), immobilising the co-amplified DNA where not already immobilised, via at
 - 20 least one PCR primer;
 - (f) assessing the amount of label on the immobilised amplified competitor DNA in each aliquot to provide an indication of the amount of target DNA in the sample.
- 25 2. A method as claimed in claim 1 in which different amounts of the competitor DNA are added to aliquots of the sample which are all at the same dilution.
3. A method as claimed in claim 2 in which the
- 30 competitor DNA is added to the aliquots as a series of dilutions.
4. A method as claimed in any of the preceding claims in which, additionally, a qualitative DIANA assay is
- 35 carried out to determine whether or not the target DNA is present in the sample and/or the total amount of amplified DNA.

- 18 -

5. A method as claimed in any of the preceding claims in which the target DNA is cDNA produced in a preliminary step from RNA, or is genomic or mitochondrial DNA.

5

6. A method as claimed in any of the preceding claims in which the recognition site in the competitor DNA is introduced by in vitro mutagenesis.

10 7. A method as claimed in any of the preceding claims in which the competitor DNA is labelled by contact with a labelled DNA binding protein.

15 8. A method as claimed in claim 7 in which the DNA binding protein is the lac repressor labelled with an enzyme.

20 9. A method as claimed in any of the preceding claims for the diagnosis of viral, bacterial, protozoal or fungal infections.

10. A kit determining the amount of target DNA in a sample including at least the following components:

25 (a) competitor DNA comprising a recognition site which is capable of being detected directly or indirectly by a labelled species;

30 (b) a label carrying means for attachment to amplified competitor DNA;

(c) a pair of primers for PCR at least one primer having means permitting immobilisation of said primer;

35

(d) a polymerase which is preferably heat stable, for example Taq1 polymerase;

- 19 -

- (e) buffers for the PCR reaction; and
- (f) optionally a solid support.

1/3





Fig.1



Introducing

Primer	Sequence	Introducing
RIT52	5'-CGGAA77CCCTCCTGATATTGATATTGATCATAAC-3'	<i>Eco</i> RI
RIT48	5'-BIOTIN-GTTCATGACTGATGTAAATA-3'	biotin
RIT54	5'-GGGGATCCCTAA77GTTATCCCGCTCACAAT77AAAGAACTTTATCTACAATAAG-3'	<i>Bam</i> HI + <i>lac</i> operator site
RIT55	5'-GGGGATCCCGAAGAAAGTGGAGGAGACATT-3'	<i>Bam</i> HI
RIT61	5'-GTGTCCATTGCTCTCATATGC-3'	
RIT53	5'-AGAAAGCTTAATAATTTCTGCCTGTACCAG-3'	<i>Hind</i> III

2/3

Fig. 2

3 / 3




Fig.3

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 91/01398

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1.5 C 12 Q 1/68 // C 07 H 21/04

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.C1.5

C 12 Q 1

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	DNA & Cell Biology, vol. 9, no. 4, April 1990, Mary Ann Liebert Inc. Publishers., J. Lundeberg et al.: "Rapid colorimetric detection of In Vitro amplified DNA sequences" pages 287-292, see the abstract, (cited in the application) ---	1-3,5-10
Y	Proc. Natl. Acad. Sci., vol. 87, April 1990, G. Gilliland et al.: "Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction", pages 2725-2729, see abstract (cited in the application) --- -/-	1-3,5-10

¹⁰ Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

14-10-1991

Date of Mailing of this International Search Report

07. 11. 91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

[Signature]

Danielle van der Haas

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	Nucleic Acids Research, vol. 17, no. 22, 1989, IRL Press, M. Becker-André et al.: "Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATY), pages 9437-9447, see abstract (cited in the application) ---	1-3,5-10
Y	G. Gilliland et al.: "Competitive PCR for quantitation of mRNA", 1990, Innis et al. editors, (San Diego, US), "PCR Protocols, a guide to methods and applications", pages 60-69, see page 61 (cited in the application) ---	1-3,5-10
P,A	WO,A,9102817 (CETUS CORP.) 07 March 1991 -----	

EP 9101398
SA 49578

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82